Posted by Michael Wonder on 01 Oct 2020
Fostamatinib in chronic immune thrombocytopenia: added benefit not proven due to lack of comparison
1 October 2020 - Only placebo controlled studies in the dossier.
Fostamatinib is approved for the treatment of adults with chronic immune thrombocytopenia who are resistant to other types of treatment (in particular to treatment with corticosteroids).
In an early benefit assessment, the Institute for Quality and Efficiency in Health Care (IQWiG) examined whether fostamatinib offers such patients an additional benefit over eltrombopag olamine or romiplostim.
